Grace Therapeutics (GRCE) Stock Price, News & Analysis

Company Overview

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Key Stats

• Today's Range: $2.89 to $3.02
• 50-Day Range: $2.79 to $3.44
• 52-Week Range: $1.75 to $4.97
• Volume: 52,348 shs
• Average Volume: 71,624 shs
• Market Capitalization: $41.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

GRCE Stock Analysis - Frequently Asked Questions

How have GRCE shares performed this year?

Grace Therapeutics' stock was trading at $3.74 at the start of the year. Since then, GRCE stock has decreased by 20.6% and is now trading at $2.97.

How were Grace Therapeutics' earnings last quarter?

Grace Therapeutics, Inc. (NASDAQ:GRCE) issued its quarterly earnings results on Friday, June, 20th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02.

Who are Grace Therapeutics' major shareholders?

Grace Therapeutics' top institutional shareholders include AIGH Capital Management LLC (8.16%) and Palumbo Wealth Management LLC (0.35%).

How do I buy shares of Grace Therapeutics?

Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 6/20/2025
• Today: 8/07/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRCE
• Previous Symbol: NASDAQ:GRCE
• CIK: 1444192
• Web: www.acastipharma.com
• Phone: 818-839-4378
• Fax: 45-0687-2272
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Grace Therapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +304.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.45%
• Return on Assets: -16.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.77
• Quick Ratio: 11.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 13,830,000
• Free Float: 12,294,000
• Market Cap: $41.08 million
• Optionable: N/A
• Beta: 0.72